Vaxart (VXRT) Stock Climbs: Here’s Why!

Vaxart VXRT Stock News

Vaxart Inc (NASDAQ: VXRT) is running for the top in the market this morning, squeezing the shorts out of their positions and putting big smiles on the faces of longs. In fact, the stock is up more than 55% early on. While the stock is flying, the company hasn’t issued any news is six days. The last SEC filing came in the beginning of January and investors are wondering what’s going on. Well, here’s why the stock is climbing:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

VXRT Flies As Coronavirus Triggers Short Squeeze

As mentioned above, Vaxart hasn’t issued any news today, but the stock is making a run for the top. So, what’s the deal? Well, it looks like a short squeeze, driven by the coronavirus.

First and foremost, recently, VXRT has been a pretty heavily shorted stock. When you see a lot of short positions, any positive news, or positive thoughts among the masses, could lead to a short squeeze and dramatic gains. So, what’s the positive?

Recently, the company has appeared in several articles on mainstream platforms, including Business Times. The topic of conversation? The company’s work to tackle coronavirus.

Coronavirus is a relatively new virus, but has become an epidemic in Asia. Unfortunately, the first case popped up in the United States, leading to concerns of a potential outbreak in the homeland.

As such, several companies that focus on the production of vaccines, including VXRT, have started to work to develop an effective vaccine against the coronavirus. This has led to excitement acorss the vaccines space, with stocks like this one, NVAX, and several others making runs for the top and squeezing shorts out of their positions.

The Race Is On

While Vaxart isn’t the only company that’s working on a vaccine to tackle the coronavirus, it has a massive opportunity here. At the end of the day, the race is on to create an effective option to ensure patients protection against the virus.

If VXRT is one of the first companies to release an effective antivirus for the coronavirus, it could be stting on a goldmine as the vaccine is likely to be in high demand, once one is created. This would be a massive win for this small biotech company. After all, an effective vaccine could generate revenues well in excess of its just over $50 million market cap annually.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.